Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Gaucher disease
Biotech
Avrobio hopes to get investors back on gene therapy bandwagon
It’s been a year since Avrobio's Fabry disease program failed. Now, the biotech is ready to reintroduce itself.
Annalee Armstrong
Dec 7, 2022 7:30am
Lilly doubles down on Prevail buy with $700M research hub
Feb 22, 2022 9:34am
Avrobio ditches Fabry, eyes 2023 trials for other gene therapies
Jan 4, 2022 10:08am
Vanqua nabs $85M from Lilly, OrbiMed, others for Gaucher, PD, AD
Sep 14, 2021 7:00am
Avrobio posts data on first Gaucher gene therapy patient
Nov 17, 2020 8:18am
European rare disease biotech Azafaros grabs $28M
Feb 6, 2020 9:03am
